- $7.92bn
- $8.28bn
- $4.53bn
- 93
- 79
- 50
- 86
Annual income statement for Amdocs, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,289 | 4,577 | 4,888 | 5,005 | 4,533 |
| Cost of Revenue | |||||
| Gross Profit | 1,478 | 1,619 | 1,728 | 1,755 | 1,722 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3,464 | 3,902 | 4,234 | 4,376 | 3,801 |
| Operating Profit | 825 | 675 | 654 | 629 | 732 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 814 | 648 | 636 | 591 | 693 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 688 | 550 | 543 | 496 | 568 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 688 | 550 | 541 | 493 | 565 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 681 | 542 | 532 | 484 | 554 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.83 | 4.37 | 5 | 5.21 | 5.65 |
| Dividends per Share |